Wall Street analysts expect Arvinas, Inc. (NASDAQ:ARVN) to post $18.68 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Arvinas’ earnings. The highest sales estimate is $41.00 million and the lowest is $5.50 million. Arvinas reported sales of $2.22 million during the same quarter last year, which indicates a positive year over year growth rate of 741.4%. The company is scheduled to announce its next quarterly earnings results on Monday, March 7th.
On average, analysts expect that Arvinas will report full year sales of $39.01 million for the current financial year, with estimates ranging from $25.90 million to $61.00 million. For the next fiscal year, analysts forecast that the company will post sales of $91.01 million, with estimates ranging from $22.00 million to $162.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Arvinas.
Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Wednesday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.13 by ($3.07). Arvinas had a negative net margin of 794.97% and a negative return on equity of 27.02%. The firm had revenue of $9.28 million for the quarter, compared to analysts’ expectations of $26.89 million. During the same quarter in the previous year, the firm posted ($0.79) EPS. The firm’s revenue for the quarter was up 22.2% compared to the same quarter last year.
In other Arvinas news, CEO John G. Houston sold 40,000 shares of the company’s stock in a transaction dated Monday, November 1st. The shares were sold at an average price of $88.14, for a total value of $3,525,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sean A. Cassidy sold 15,000 shares of the company’s stock in a transaction dated Friday, December 17th. The shares were sold at an average price of $70.00, for a total transaction of $1,050,000.00. The disclosure for this sale can be found here. Insiders sold a total of 497,657 shares of company stock valued at $38,807,660 over the last quarter. 6.45% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the company. Credit Suisse AG lifted its position in shares of Arvinas by 0.6% in the 3rd quarter. Credit Suisse AG now owns 30,888 shares of the company’s stock valued at $2,538,000 after acquiring an additional 193 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Arvinas by 0.4% during the 3rd quarter. Alliancebernstein L.P. now owns 55,000 shares of the company’s stock valued at $4,520,000 after purchasing an additional 200 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Arvinas by 1.2% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 17,452 shares of the company’s stock valued at $1,434,000 after purchasing an additional 210 shares in the last quarter. Advisor Group Holdings Inc. raised its holdings in shares of Arvinas by 142.7% during the 3rd quarter. Advisor Group Holdings Inc. now owns 415 shares of the company’s stock valued at $34,000 after purchasing an additional 244 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Arvinas by 3.5% during the 2nd quarter. AQR Capital Management LLC now owns 8,538 shares of the company’s stock valued at $657,000 after purchasing an additional 291 shares in the last quarter. Institutional investors and hedge funds own 89.31% of the company’s stock.
Shares of ARVN traded up $2.38 during mid-day trading on Friday, reaching $67.42. The company had a trading volume of 478,996 shares, compared to its average volume of 355,990. Arvinas has a 52-week low of $56.59 and a 52-week high of $108.46. The stock has a market capitalization of $3.56 billion, a P/E ratio of -17.71 and a beta of 1.93. The stock has a 50 day moving average of $77.35 and a two-hundred day moving average of $83.77.
Arvinas, Inc is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
Read More: Strike Price
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.